[1]
|
M. L. Rosenblum, “Chemosensitivity Testing for Human Brain Tumors,” Progress in Clinical and Biological Research, Vol. 48, 1980, pp. 259-276.
|
[2]
|
U. Bogdahn, “Chemosensitivity of Malignant Human Brain Tumors. Preliminary Results,” Journal of Neurooncology, Vol. 1, No. 2, 1983, pp.149-166.
doi:10.1007/BF00182961
|
[3]
|
G. Nikkhah, J. C. Tonn, O. Hoffmann, H. P. Kraemer, J. L. Darling, W. Schachenmayr and R. Schonmayr “The MTT Assay for Chemosensitivity Testing of Human Tumors of the Central Nervous System. Part II: Evaluation of Patient- and Drug-Specific Variables” Journal of Neurooncology, Vol. 13 No. 1, 1992, pp. 13-24.
doi:10.1007/BF00172942
|
[4]
|
J. C. Tonn, W. Schachenmayr and H. P. Kraemer, “In Vitro Chemosensitivity Test of Malignant Gliomas: Clinical Relevance of Test Results Independent of Adjuvant Chemotherapy,” Anticancer Research, Vol. 14, No. 3B, 1994, pp. 1371-1375.
|
[5]
|
L. Mollgard, M. Prenkert, A. Smolowicz, C. Paul and U. Tidefelt, “In Vitro Chemosensitivity Testing of Selected Myeloid Cells in Acute Myeloid Leukemia,” Leukemia and Lymphoma, Vol. 44, No. 5, 2003, pp. 783-789.
doi:10.1080/1042819031000067594
|
[6]
|
L. Mollgard, U. Tidefelt, B. Sundman-Engberg, C. Lofgren and C. Paul, “In Vitro Chemosensitivity Testing in Acute Non Lymphocytic Leukemia Using the Bioluminescence ATP Assay,” Leukemia Research, Vol. 24, No. 5, 2000, pp. 445-452.
doi:10.1016/S0145-2126(00)00003-5
|
[7]
|
T. Hayon, A. Dvilansky, O. Shpilberg and I. Nathan, “Appraisal of the MTT-Based Assay as a Useful Tool for Predicting Drug Chemosensitivity in Leukemia,” Leukemia and Lymphoma Vol. 44, No. 11, 2003, pp. 1957-1962.
doi:10.1080/1042819031000116607
|
[8]
|
A. Desjardins, J. N. Rich, J. A. Quinn, J. Vredenburgh, S. Gururangan, S. Sathornsumetee, D. A. Reardon, A. H. Friedman, D. D. Bigner and H. S. Friedman, “Chemotherapy and Novel Therapeutic Approaches in Malignant Gliomas,” Frontiers in Bioscience, Vol. 10, 2005, pp. 2645-2668. doi:10.2741/1727
|
[9]
|
M. G. Castro, R. Cowen, I. K. Williamson, A. David, M. J. Jimenez-Dalmaroni, X. Yuan, A. Bigliari, J. C. Williams, J. Hu and P. R. Lowenstein, “Current and Future Strategies for the Treatment of Malignant Brain Tumors,” Pharmacology and Therapeutics, Vol. 98, No. 1, 2003, pp. 71-108. doi:10.1016/S0163-7258(03)00014-7
|
[10]
|
N. G. Avgeropoulos and T. T. Batchelor, “New Treatment Strategies for Malignant Gliomas,” Oncologist, Vol. 4, No. 3, 1999, pp. 209-224.
|
[11]
|
T. Mosmann, “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays,” Journal of Immunological Methods, Vol. 65, No. 1-2, 1983, pp. 55-63.
doi:10.1016/0022-1759(83)90303-4
|
[12]
|
A. H. Cory, T. C. Owen, J. A. Barltrop and J. G. Cory, “Use of an Aqueous Soluble Tetrazolium Formazan Assay for Cell-Growth Assays in Culture,” Cancer Communications, Vol. 3, No. 7, 1991, pp. 207-212.
|
[13]
|
S. P. M. Crouch, R. Koslowski, K. J. Slater and J. F. Fletcher, “The Use of ATP-Bioluminescence in Cytokine Bioassays as a Measure of Cell Proliferation and Cytotoxicity,” Lymphokine and Cytokine Research, Vol. 12, No. 5, 1993, pp. 397-397.
|
[14]
|
A. T. O’Meara and B. U. Sevin, “Predictive Value of the ATP Chemosensitivity Assay in Epithelial Ovarian Cancer,” Gynecologic Oncology, Vol. 83, No. 2, 2001, pp. 334-342. doi:10.1006/gyno.2001.6395
|
[15]
|
K. Endo, Y. Maehara, T. Kusumoto, Y. Ichiyoshi, M. Kuwano and K. Sugimachi, “Expression of Multidrug- Resistance-Associated Protein (MRP) and Chemosensitivity in Human Gastric Cancer,” International Journal of Cancer, Vol. 68, No. 3, 1996, pp. 372-377.
doi:10.1002/(SICI)1097-0215(19961104)68:3<372::AID-IJC16>3.0.CO;2-A
|
[16]
|
H. Kawamura, K. Ikeda, I. Takiyama and M. Terashima, “The Usefulness of the ATP Assay with Serum-Free Culture for Chemosensitivity Testing of Gastrointestinal Cancer,” European Journal of Cancer. Vol. 33, No. 6, 1997, pp. 960-966. doi:10.1016/S0959-8049(97)00075-0
|
[17]
|
C. M. Kurbacher, O. M. Grecu, U. Stier, T. J. Gilster, M. M. Janat, M. Untch, G. Konecny, H. W. Bruckner and I. A. Cree, “ATP Chemosensitivity Testing in Ovarian and Breast Cancer: Early Clinical Trials: Recent Results,” Cancer Research, Vol. 161, 2003, pp. 221-230.
|
[18]
|
S. Sharma, M. H. Neale, F. Di Nicolantonio, L. A. Knight, P. A. Whitehouse, S. J. Mercer, B. R. Higgins, A. Lamont, R. Osborne, A. C. Hindley, C. M/ Kurbacher and I. A. Cree, “Outcome of ATP-Based Tumor Chemosensitivity Assay Directed Chemotherapy in Heavily Pre-Treated Recurrent Ovarian Carcinoma,” BMC Cancer, Vol. 3, No. 19, 2003.
http://www.biomedcentral.com/1471-2407/3/19
|
[19]
|
T. P. Dawson, R. V. Iyer, R. W. Lea, P. Roberts, F. Harris, K. Ashton, A. Golash and C. H. G. Davis, “The MTS Versus the ATP Assay for in Vitro Chemosensitivity Testing of Primary Glioma Tissue Culture,” Neuropathology and Applied Neurobiology, Vol. 36, No. 6, 2010, pp. 564-567. doi:10.1111/j.1365-2990.2010.01096.x
|
[20]
|
D. E. Thurston, “Chemistry and Pharmacology of Anticancer Drugs,” CRC Press, Oxford, 2006.
doi:10.1201/9781420008906
|
[21]
|
H. B. Newton, “Intra-Arterial Chemotherapy of Primary Brain Tumors,” Current Treatment Options in Oncology, Vol. 6, No. 6, 2005, pp. 519-530.
doi:10.1007/s11864-005-0030-1
|
[22]
|
National Institute for Health and Clinical Excellence, “Glioma (Newly Diagnosed and High Grade)—Carmustine Implants and temozolomide: Appraisal Consultation Document,” 2010.
|
[23]
|
S. H. Tseng, M. S. Bobola, M. S. Berger and J. R. Silber, “Characterization of Paclitaxel (Taxol) Sensitivity in Human Glioma-and Medulloblastoma-Derived Cell Lines,” Neuro-Oncology, Vol. 1, No. 2, 1999, pp. 101-108.
|
[24]
|
M. Zhao, C. Liang, A. M. Li, J. Chang, H. J. Wang, R. M. Yan, J. J. Zhang and J. L. Tai, “Magnetic Paclitaxel Nanoparticles Inhibit Glioma Growth and Improve the Survival of Rats Bearing Glioma Xenografts,” Anticancer Research, Vol. 30, No. 6, 2010, pp. 2217-2223.
|
[25]
|
M. M. Mrugala, S. Kesari, N. Ramakrishna and P. Y. Wen, “Therapy for Recurrent Malignant Glioma in Adults,” Expert Review of Anticancer Therapy, Vol. 4, No. 5, 2004, pp. 759-782. doi:10.1586/14737140.4.5.759
|
[26]
|
R. V. Iyer, “A feasibility Study of Chemosensitivity Testing in Primary Cultures from Malignant Gliomas, and Analysis of Drug Resistance Mechanisms,” MD, University of Central Lancashire, 2006.
|
[27]
|
M. Westphal, Z. Ram, V. Riddle, D. Hilt and E. Bortey, and on Behalf of the Executive Committee of the Gliadel Study Group, “Gliadel (R) Wafer in Initial Surgery for Malignant Glioma: Long-Term Follow-up of a Multicenter Controlled Trial,” Acta Neurochirurgica, Vol. 148, No. 3, 2006, pp. 269-275.
doi:10.1007/s00701-005-0707-z
|
[28]
|
N. D. Doolittle, M. E. Miner, W. A. Hall, T. Siegal, E. J. Hanson, E. Osztie, L. D. McAllister, J. S. Bubalo, D. F. Kraemer, D. Fortin, R. Nixon, L. L. Muldoon and E. A. Neuwelt, “Safety and Efficacy of a Multicenter Study Using Intraarterial Chemotherapy in Conjunction with Osmotic Opening of the Blood-Brain Barrier for the Treatment of Patients with Malignant Brain Tumors,” Cancer, Vol. 88, No. 3, 2000, pp. 637-647.
doi:10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y
|
[29]
|
Z. Lidar, Y. Mardor, T. Jonas, R. Pfeffer, M. Faibel, D. Nass, M. Hadani and Z. Ram, “Convection-Enhanced Delivery of Paclitaxel for the Treatment of Recurrent Malignant Glioma: A Phase I/II Clinical Study,” Journal of Neurosurgery, Vol. 100, No. 3, 2004, pp. 472-479.
doi:10.3171/jns.2004.100.3.0472
|
[30]
|
W. K. Yung, J. R. Shapiro and W. R. Shapiro, “Heterogeneous Chemosensitivities of Subpopulations of Human Glioma Cells in Culture,” Cancer Research, Vol. 42, No. 3, 1982, pp. 992-998.
|